The news today really makes me confident in the emphasis IPIX has put on a partnership in 2017. My view of a B deal was that the B-OM component was the last key indication since it is relatively easy to administer and it is for an unmet medical need. I imagine that BP gets a look at any available interim data and that a deal could become effective when the topline results are in or sooner.....all the while P marches on and K as well. All IMHO of course.